The oral administration of protein and peptide drugs is often described as the "holy grail" of pharmacology. While highly desirable for patient convenience and cost-effectiveness, the gastrointestinal (GI) tract presents a formidable gauntlet of biochemical and physical barriers. As Lou et al. and Cao et al. explain, therapeutic biologics face a hostile environment characterized by extreme pH levels in the stomach, a dense thicket of proteolytic enzymes, and a viscous mucus layer. These factors typically result in oral bioavailability of less than 2%, as noted by Jiang et al., necessitating invasive injections for long-term treatments.
Current research focuses on three primary strategies to navigate this environment: structural fortification of the molecules themselves, the engineering of protective nanocarriers, and the development of targeted delivery vehicles that can anchor to specific regions of the gut.
Structural Fortification Against Proteolysis
One way to survive the GI tract is to modify the peptide's structure so that digestive enzymes no longer recognize it as a substrate. Proteases are highly stereospecific; they are evolved to break down L-amino acids found in nature. By synthesizing "mirror-image" peptides using D-amino acids, researchers can create molecules that are virtually invisible to these enzymes. Jiang et al. demonstrated that the D-enantiomeric peptide D3 achieves a remarkably high oral bioavailability of 58% because it remains exceptionally stable against enzymatic degradation.
Other structural strategies include:
- Cyclization: By linking the head and tail of a peptide, researchers can restrict its conformational flexibility, making it harder for proteases to bind and cleave the backbone. Karami et al. developed computational frameworks to design these linkers, while Chin et al. validated cyclic peptides that maintain stability while targeting specific gut proteins.
- Lasso Peptides: Nature provides its own stable scaffolds, such as "lasso peptides" like Microcin Y. Wenjing Li et al. showed that these specialized structures are naturally resistant to high temperatures and proteolytic enzymes, allowing them to reach the gut in a functional state to treat infections.
Protective Nanocarriers and Micelles
If the drug molecule itself cannot be made stable, it must be shielded. Nanotechnology offers a way to encapsulate sensitive payloads within protective shells. Zhang et al. utilized alginate-chitosan microspheres to encapsulate insulin, protecting it from gastric acid and providing sustained release. Similarly, Wendy Wu et al. developed glycosylated protein nanoparticles (BSA-dextran) to shield marine-derived peptides, finding that pre-loading the peptide into the nanoparticle significantly improved its bioaccessibility.
The choice of material is critical for navigating the mucus barrier. Yiming Li et al. developed pea albumin nanomicelles (PANs) that are not only stable in the GI environment but also possess enhanced mucus permeability. By shielding hydrophobic drugs within a stable protein shell, these micelles can bypass the "washout" effect of the mucus layer, delivering the payload directly to the intestinal epithelium.
Targeted Localization and Mechanical Delivery
Beyond simple protection, researchers are developing systems that actively navigate to and stay at the site of absorption. Subramanian et al. and Chin et al. identified small-molecule and cyclic peptide ligands that bind selectively to specific mucin glycoproteins (like MUC5AC in the stomach or MUC2 in the intestine). By decorating drug carriers with these ligands, the authors achieved up to a 25-fold increase in local drug concentration, effectively turning the mucus layer from a barrier into a target.
For even more precise delivery, micro-fabricated devices and robotics are being explored:
- Microcontainers: Mazzoni et al. designed detachable microcontainers that protect drugs from premature release and degradation, significantly increasing the bioavailability of small molecules by ensuring they are released only when in close contact with the intestinal wall.
- Microrobots: Ren et al. reviewed the potential of active propulsion methods, where microrobots can physically penetrate the mucus layer or resist mechanical forces in the gut to deliver biologics directly to the absorption site.
As Rongjun Zou et al. and Yansong Guo et al. emphasize, the transition from animal models to human clinical use requires these sophisticated delivery mechanisms to maintain the structural integrity of signaling peptides and mimetic molecules. By combining structural stabilization with advanced engineering, the field is moving closer to making oral delivery a reality for even the most fragile biological drugs.
Key Foundational Work
Preparation and evaluation of alginate–chitosan microspheres for oral delivery of insulin (2010) — contributed 2 concept elements to this direction.
Odorranalectin Is a Small Peptide Lectin with Potential for Drug Delivery and Targeting (2008) — contributed 2 concept elements to this direction.